FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience (Q24622390)

19

Carlos Fernandez-del Castillo

0 references

Keith D Lillemoe

12

Keith D Lillemoe

0 references

Eunice L Kwak

11

Eunice L Kwak

0 references

Jeffrey W Clark

18

Jeffrey W Clark

0 references

David P Ryan

20

David P Ryan

0 references

Lawrence S Blaszkowsky

2

Lawrence S Blaszkowsky

0 references

Theodore S Hong

21

Theodore S Hong

0 references

Jennifer Wargo

8

Jennifer A Wargo

0 references

author name string

Jason E Faris

1

0 references

Shaunagh McDermott

3

0 references

Alexander R Guimaraes

4

0 references

Jackie Szymonifka

5

0 references

Mai Anh Huynh

6

0 references

Cristina R Ferrone

7

0 references

Jill N Allen

9

0 references

Lauren E Dias

10

0 references

Sarah P Thayer

13

0 references

Janet E Murphy

14

0 references

Andrew X Zhu

15

0 references

Dushyant V Sahani

16

0 references

Jennifer Y Wo

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

17

0 references

language of work or name

English

0 references

publication date

2013

0 references

published in

Oncologist

0 references

volume

18

0 references

issue

5

0 references

page(s)

543-8

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662845

7 April 2017

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662845

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662845

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662845

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662845

Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662845

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662845

A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662845

Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662845

Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662845

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662845

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662845

Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662845

Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy

28 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23657686

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Locally advanced pancreatic cancer: where should we go from here?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23657686

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23657686

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1634/THEONCOLOGIST.2012-0435

1 reference

4705140

4705140

1 reference

1 reference

1 reference